Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR-γ Agonist against MPTP

Figure 4

LSN862 (LSN) affected mRNA expression at 24 hrs, 72 hrs, and 21 days post-MPTP. Quantitative PCR analysis of nigral (a) gp91 phox, (b) SOD2, (c) MAC-1, and (d) GFAP and striatal (e) PPAR-γ, (f) PGC1α mRNA levels. The groups were vehicle + PBS (24 hrs: 𝑛=5; 72 hrs: 𝑛=4; 21 days: 𝑛=4); vehicle + MPTP (24 hrs: 𝑛=5; 72 hrs: 𝑛=5; 21 days: 𝑛=6); 30 mg/kg LSN + PBS (24 hrs: 𝑛=4; 72 hrs: 𝑛=3; 21 days 𝑛=4; 30 mg/kg LSN + MPTP (24 hrs: 𝑛=5; 72 hrs 𝑛=4; 21 days 𝑛=5). Data is expressed as fold change from vehicle + PBS controls relative to 𝛽-actin (mean ± SEM). Two-way ANOVA with repeated measures, ^#𝑃<0.05 (vehicle + MPTP versus vehicle + PBS), *𝑃<0.05 (vehicle + MPTP versus 30 mg/kg LSN + MPTP), and **𝑃<0.05 (vehicle + PBS versus 30 mg/kg LSN + PBS).

(a)

(b)

(c)

(d)

(e)

(f)